Israeli AI cardiac ultrasound co UltraSight raises $13m
UltraSight’s AI platform provides the engine for ultrasound devices to conduct sonography at the point of care, helping more patients be accurately diagnosed and treated.
Israeli AI cardiac ultrasound company UltraSight (formerly OnSight Medical) announced today that it has closed a $13 million Series B financing round with the participation of the Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science The investment will be used to advance US clinical programs for UltraSight s real time, AI guidance for cardiac ultrasound in a variety of care settings.
UltraSight CEO Davidi Vortman said, UltraSight provides a novel and versatile platform that addresses the unmet needs of patients and physicians. This financing round places us on the path to become a leading player in the ultrasound industry.
UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care
USA - English
News provided by
Share this article
Share this article
TEL AVIV, Israel, May 11, 2021 /PRNewswire/ UltraSight (formerly OnSight Medical), a Digital Health pioneer for cardiac imaging and beyond, announced today that it has closed a $13 million Series B funding round. The investment will be used to advance U.S. clinical programs for its real time, AI guidance in a variety of care settings. The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.
UltraSight s AI platform provides the engine for ultrasound devices to conduct sonography at the point of care, helping more patients be accurately diagnosed and treated. Point of care ultrasound allows medical professionals to diagnose patients wherever they are including clinics, community hospitals, ambulances and remote settings. Currently, cardiac sonogr